|
Notes
from Pharma's Executive Suites
Merck
& Co. CEO Richard T. Clark received $14.5 million in
compensation last year—an 80% increase. Clark’s base salary
was $1.62 million in 2007, up 37% from his 2006 base pay. Most of
Clark’s compensation came from the value of stock and options
granted to him last year. Clark has been Merck’s CEO and
president since May 2005. AP/BusinessWeek
(3/10)
AstraZeneca CEO David Brennan
received $4.31 million in compensation last year—a 19% decrease.
While Brennan’s salary went up in 2007, he received fewer
reimbursements and his bonus decreased vis-à-vis 2006. Brennan
took over as CEO in January 2006 and relocated from the US to the
UK. Bloomberg.com
(3/6)
Bristol-Myers
Squibb CFO Andrew Bonfield, who joined the company about six years
ago, is leaving. He will be succeeded by Jean-Marc Huet effective
March 31. Huet previously served as CFO at Royal Numico N.V. in
Amsterdam. Another executive change: Bristol-Myers elevated
Lamberto Andreotti from chief operating officer of worldwide
pharmaceuticals to chief operating officer of the entire company. Reuters
(3/5)
Lundbeck’s
president and chief executive, Claus Braestrup, has resigned.
While he was due to retire, Braestrup’s departure came earlier
than expected. Per Wold-Olsen, who is chairman of the supervisory
board, will act as executive chairman until Braestrup’s
replacement is found. Reuters
(3/5)
|
